Clinical Trials for Kidney Cancer

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic hepatocellular, renal cell, breast, ovarian/fallopian, or endometrial/primary peritoneal cancers involving the abdomen or thorax who have progressed on or are intolerant to standard therapies, and evaluates safety of Tumor Treating Fields (TTF) in combination with either cabozantinib (a multi-kinase inhibitor targeting MET, VEGFR, and AXL) or nab-paclitaxel plus atezolizumab (a PD-L1 inhibitor).

ClinicalTrials.gov ID: NCT05092373

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced unresectable or metastatic solid tumors (including a broad range such as ovarian, pancreatic, GI, lung, and more) or relapsed/refractory multiple myeloma who have failed or are intolerant to standard therapies are eligible to receive QXL138AM, a masked anti-CD138 immunocytokine fused to interferon alpha-2a designed for tumor-targeted immune activation.

ClinicalTrials.gov ID: NCT06582017

A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing Cancers

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with metastatic or unresectable CD70-expressing cancers (including clear cell renal cell carcinoma and other solid tumors) who have progressed after at least one prior therapy, to receive a lymphodepleting regimen followed by infusion of autologous T cells genetically engineered with an anti-CD70 chimeric antigen receptor targeting CD70-positive tumor cells, plus high-dose aldesleukin (IL-2) post-infusion.

ClinicalTrials.gov ID: NCT02830724

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with advanced/metastatic solid tumors lacking standard options; dose-escalation all-comers followed by expansion in biomarker-selected cohorts including NSCLC with YES1 or TYMS amplification or FAT1 mutation, renal cancer or mesothelioma with NF2 mutation, and other tumors with NF2/FAT1/LATS1 mutations or TYMS/YAP1/YES1/TAZ1 amplifications. Treatment is NXP900, an oral conformation-selective SRC family kinase inhibitor with high potency against YES1/SRC, given as monotherapy.

ClinicalTrials.gov ID: NCT05873686

A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced/metastatic c‑Kit–expressing solid tumors (including GIST, SCLC, adenoid cystic carcinoma, uveal melanoma, NETs, chromophobe or clear‑cell RCC) who have progressed after or are ineligible/intolerant to standard therapy receive NN3201, an IV c‑Kit (CD117)–targeted antibody‑drug conjugate delivering MMAE every 3 weeks. Expansion cohorts include GIST (post‑imatinib), SCLC, and other c‑Kit–positive tumors to assess safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT06805825

Phase I/II Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults and adolescents (16–80 years) with CD70-positive advanced clear cell RCC (post PD-1/PD-L1 and anti-angiogenic therapy), mesothelioma (progressive after standard options including checkpoint blockade), or osteosarcoma (recurrent/refractory after anthracycline) receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of allogeneic cord blood–derived CAR NK cells targeting CD70 via a CD27-based CAR, armored with IL-15 for persistence and containing an inducible caspase-9 safety switch. Single-arm dose-escalation/expansion evaluates safety, dose, persistence, and preliminary activity.

ClinicalTrials.gov ID: NCT05703854

Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Patients With SOLID TUMORS (CATCH)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory GPC3-positive solid tumors (including HCC meeting BCLC A–C and Child-Pugh <7) receive lymphodepleting cyclophosphamide/fludarabine followed by a single infusion of autologous GPC3-targeted CAR T cells engineered to express IL-15 for enhanced persistence and an inducible caspase-9 safety switch. Key exclusions include prior organ transplant, uncontrolled infection, HIV, pregnancy, high-dose steroids at infusion, and murine protein hypersensitivity/HAMA.

ClinicalTrials.gov ID: NCT05103631

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with metastatic rare genitourinary cancers across multiple histologic cohorts (e.g., small cell/neuroendocrine bladder, variant urothelial, penile, sarcomatoid/unclassified RCC, collecting duct, renal medullary, urethral; including a bone-only GU cohort), with up to two prior lines allowed (cohort-specific exceptions. Patients receive cabozantinib (MET/VEGFR2/AXL multi-kinase inhibitor) plus nivolumab (PD-1) and ipilimumab (CTLA-4) for up to 2 years.

ClinicalTrials.gov ID: NCT03866382

An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic renal cell carcinoma, urothelial carcinoma, or castration-resistant prostate cancer receive oral DCC-2812 monotherapy, a first-in-human, selective GCN2 activator that engages the integrated stress response (eIF2α phosphorylation/ATF4) to disrupt tumor survival pathways. Dose-escalation evaluates safety, dose-limiting toxicities, and PK, with preliminary antitumor activity assessed.

ClinicalTrials.gov ID: NCT06966024

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic clear cell RCC (any VHL status) receive oral HC-7366—an activator of the GCN2 integrated stress response pathway—either alone or combined with belzutifan (HIF-2α inhibitor), with combination dose escalation/expansion to define MTD/RP2D. Suitable for patients needing a belzutifan-based regimen or eligible for first- or later-line investigational therapy in ccRCC.

ClinicalTrials.gov ID: NCT06234605